BIO vs QNCX · rev $651.0M vs $79.3M cap
BIO (BIO) versus Quince Therapeutics, Inc. (QNCX) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Quince Therapeutics, Inc. (QNCX) is a biotechnology company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
QNCX does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. QNCX currently screens at market cap $79.3M.
Not investment advice. Open the BIO and QNCX stock pages for the full models.
Not investment advice.